查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2152328

心絞痛治療藥物市場規模、佔有率和趨勢分析報告：按類型、藥物類別、分銷管道、地區和細分市場分類（2026-2033 年）

Angina Pectoris Drugs Market Size, Share & Trends Analysis Report By Type (Stable Angina, Unstable Angina, Microvascular Angina, Prinzmetal Angina), By Drug Class, By Distribution Channel, By Region, And Segment Forecasts, 2026 - 2033
出版日期: | 出版商: Grand View Research | 英文 120 Pages | 商品交期: 2-10個工作天內

價格
簡介目錄

據估計，2025 年全球心絞痛治療市場價值為 129 億美元，預計從 2026 年的 134 億美元成長到 2033 年的 176 億美元，2026 年至 2033 年的年複合成長率（CAGR）為 4.0%。

北美在全球市場中處於領先地位，預計到 2025 年將佔據 40.0% 的最大銷售佔有率。個人化心血管醫學和新型藥物輸送系統的進步正在推動市場擴張。

此外，包括冠狀動脈疾病在內的心臟病發病率不斷上升，正在推動全球市場成長。製藥公司正大力投資臨床試驗，以開發出更療效的創新療法，這進一步加速了市場成長。預計這些趨勢將顯著促進市場的持續擴張。

全球心絞痛治療市場受多種因素驅動，其中包括全球心血管疾病發生率的上升。心血管疾病是全球主要死因之一，這一事實促使人們對有效治療方法的需求日益成長。藥物傳遞系統的進步，例如經皮貼片和緩釋製劑，也正在提高心絞痛治療的療效和病人依從性。

人口老化也是推動市場發展的主要動力之一，因為老年人更容易罹患心血管疾病。這種人口結構的變化為製藥公司提供了開發針對老年人獨特需求並改善其生活品質的標靶療法的機會。製藥公司與研究機構之間的策略合作和聯合研究也透過加速藥物發現和促進創新製劑的開發，推動了市場成長。

循環系統疾病治療的進步、持續的研發投入以及FDA等監管機構批准藥物數量的增加，都在推動市場成長。零售藥局的興起以及患者更傾向於透過這些管道購買心絞痛藥物，也創造了市場機會。隨著全球人口老化，對有效心絞痛治療的需求將持續成長，這為製藥公司開發和銷售滿足這一日益成長需求的新產品提供了機會。

目錄

第1章：調查方法和範圍

第2章執行摘要

第3章 心絞痛藥物市場：變數、趨勢與範圍

  • 市場概況及未來展望
  • 市場規模和成長前景
  • 市場動態
  • 心絞痛治療藥物市場分析工具

第4章：心絞痛治療藥物市場：按類型分類的估算與趨勢分析

  • 心絞痛治療市場：按類型分類的趨勢分析，2026 年和 2033 年
  • 穩定性心絞痛
  • 不穩定型心絞痛
  • 微血管性心絞痛
  • Prinzmetal型心絞痛

第5章：心絞痛治療藥物市場：依藥物類別分類的估算與趨勢分析

  • 心絞痛治療市場：按藥物類別分類的趨勢分析，2026 年和 2033 年
  • BETA阻斷劑
  • 鈣通道阻斷劑
  • 硝酸酯類藥物
  • 抗凝血物
  • 抗血小板藥物
  • 其他藥物分類

第6章：心絞痛治療藥物市場：按分銷管道分類的估算與趨勢分析

  • 心絞痛治療市場：按分銷管道分類的趨勢分析（2026 年和 2033 年）
  • 醫院藥房
  • 零售藥房
  • 網路藥房

第7章 心絞痛治療藥物市場：區域估算與趨勢分析

  • 2026 年及 2033 年各地區心絞痛藥物市場佔有率
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • UAE
    • 科威特

第8章 競爭情勢

  • 主要市場參與企業的最新趨勢及影響分析
  • 公司分類
  • 企業熱力圖分析
  • 公司簡介
    • Pfizer Inc.
    • Bayer AG
    • AstraZeneca
    • Gilead Sciences
    • Novartis AG
    • GlaxoSmithKline Plc.
    • Merck & Co., Inc.
    • Amgen Inc.
    • Eli Lilly and Company
    • Otsuka Pharmaceutical Co., Ltd.
    • Sanofi SA
    • Boehringer Ingelheim International GmbH
簡介目錄
Product Code: GVR-2-68038-045-3

The global angina pectoris drugs market size was valued at USD 12.9 billion in 2025 and is projected to grow from USD 13.4 billion in 2026 to USD 17.6 billion by 2033, at a CAGR of 4.0% from 2026 to 2033. The North America dominated the global market, accounting for the largest revenue share of 40.0% in 2025. Advancements in personalized cardiovascular medicine and novel drug delivery systems are driving market expansion.

Moreover, worldwide market growth is fueled by the escalating prevalence of cardiac disorders, including coronary heart disease. Pharmaceutical companies are investing heavily in clinical trials to develop innovative treatments with improved efficacy, further propelling market growth. These developments are expected to significantly contribute to the market's continued expansion.

The global angina pectoris drugs market is driven by a combination of factors, including the increasing occurrence of cardiovascular diseases worldwide. The growing demand for effective treatments is driven by the fact that cardiovascular diseases are a leading contributor to global mortality rates. Advances in drug delivery systems, such as transdermal patches and sustained-release formulations, are also boosting the efficiency and patient compliance of angina pectoris medications.

The growing geriatric population is another key driver of the market, as the elderly are more susceptible to cardiovascular diseases. This demographic shift presents an opportunity for pharmaceutical companies to develop targeted therapies that address the unique needs of older adults and improve their quality of life. Strategic partnerships and collaborations between pharmaceutical companies and research institutions are also driving market growth by advancing the development of innovative drug formulations and accelerating drug discovery.

Advancements in cardiology treatment, ongoing research and development efforts, and a growing number of drug approvals from regulatory bodies such as the FDA are also driving market growth. The rise in retail pharmacies and patient preference for purchasing angina drugs through these channels is creating market opportunities. As the global population continues to age, there will be increasing demand for effective treatments for angina pectoris, presenting an opportunity for pharmaceutical companies to develop and market new products to meet this growing need.

Global Angina Pectoris Drugs Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global angina pectoris drugs market report by type, drug class, distribution channel, and region:

  • Type Outlook (Revenue, USD Billion, 2021 - 2033)

Stable Angina

Unstable Angina

Microvascular Angina

Prinzmetal Angina

  • Drug Class Outlook (Revenue, USD Billion, 2021 - 2033)

Beta Blockers

Calcium Antagonists

Nitrates

Anticoagulants

Anti-Platelets

Other Drug Classes

  • Distribution Channel Outlook (Revenue, USD Billion, 2021 - 2033)

Hospital Pharmacy

Retail Pharmacy

Online Pharmacy

  • Regional Outlook (Revenue, USD Billion, 2021 - 2033)

North America

    • U.S.
    • Canada
    • Mexico

Europe

    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway

Asia Pacific

    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand

Latin America

    • Brazil
    • Argentina

Middle East & Africa

    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
    • 1.3.1. Information Procurement
    • 1.3.2. Information or Data Analysis
    • 1.3.3. Market Formulation & Data Visualization
    • 1.3.4. Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Angina Pectoris Drugs Market Variables, Trends, & Scope

  • 3.1. Market Introduction/Lineage Outlook
  • 3.2. Market Size and Growth Prospects (USD Million)
  • 3.3. Market Dynamics
    • 3.3.1. Market Drivers Analysis
    • 3.3.2. Market Restraints Analysis
  • 3.4. Angina Pectoris Drugs Market Analysis Tools
    • 3.4.1. Porter's Analysis
      • 3.4.1.1. Bargaining power of the suppliers
      • 3.4.1.2. Bargaining power of the buyers
      • 3.4.1.3. Threats of substitution
      • 3.4.1.4. Threats from new entrants
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Economic and Social landscape
      • 3.4.2.3. Technological landscape
      • 3.4.2.4. Environmental landscape
      • 3.4.2.5. Legal landscape

Chapter 4. Angina Pectoris Drugs Market: Type Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Angina Pectoris Drugs Market: Type Movement Analysis, 2026 & 2033 (USD Million)
  • 4.3. Stable Angina
    • 4.3.1. Stable Angina Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.4. Unstable Angina
    • 4.4.1. Unstable Angina Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.5. Microvascular Angina
    • 4.5.1. Microvascular Angina Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.6. Prinzmetal Angina
    • 4.6.1. Prinzmetal Angina Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Angina Pectoris Drugs Market: Drug Class Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Angina Pectoris Drugs Market: Drug Class Movement Analysis, 2026 & 2033 (USD Million)
  • 5.3. Beta Blockers
    • 5.3.1. Beta Blockers Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.4. Calcium Antagonists
    • 5.4.1. Calcium Antagonists Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.5. Nitrates
    • 5.5.1. Nitrates Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.6. Anticoagulants
    • 5.6.1. Anticoagulants Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.7. Anti-Platelets
    • 5.7.1. Anti-Platelets Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.8. Other Drug Classes
    • 5.8.1. Other Drug Classes Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Angina Pectoris Drugs Market: Distribution Channel Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Angina Pectoris Drugs Market: Distribution Channel Movement Analysis, 2026 & 2033 (USD Million)
  • 6.3. Hospital Pharmacy
    • 6.3.1. Hospital Pharmacy Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.4. Retail Pharmacy
    • 6.4.1. Retail Pharmacy Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5. Online Pharmacy
    • 6.5.1. Online Pharmacy Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Angina Pectoris Drugs Market: Regional Estimates & Trend Analysis

  • 7.1. Angina Pectoris Drugs Market Share, By Region, 2026 & 2033 (USD Million)
  • 7.2. North America
    • 7.2.1. North America Angina Pectoris Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.2.2. U.S.
      • 7.2.2.1. U.S. Angina Pectoris Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.2.3. Canada
      • 7.2.3.1. Canada Angina Pectoris Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.2.4. Mexico
      • 7.2.4.1. Mexico Angina Pectoris Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.3. Europe
    • 7.3.1. Europe Angina Pectoris Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.3.2. UK
      • 7.3.2.1. UK Angina Pectoris Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.3.3. Germany
      • 7.3.3.1. Germany Angina Pectoris Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.3.4. France
      • 7.3.4.1. France Angina Pectoris Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.3.5. Italy
      • 7.3.5.1. Italy Angina Pectoris Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.3.6. Spain
      • 7.3.6.1. Spain Angina Pectoris Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.3.7. Denmark
      • 7.3.7.1. Denmark Angina Pectoris Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.3.8. Sweden
      • 7.3.8.1. Sweden Angina Pectoris Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.3.9. Norway
      • 7.3.9.1. Norway Angina Pectoris Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.4. Asia Pacific
    • 7.4.1. Asia Pacific Angina Pectoris Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.2. Japan
      • 7.4.2.1. Japan Angina Pectoris Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.3. China
      • 7.4.3.1. China Angina Pectoris Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.4. India
      • 7.4.4.1. India Angina Pectoris Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.5. Australia
      • 7.4.5.1. Australia Angina Pectoris Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.6. South Korea
      • 7.4.6.1. South Korea Angina Pectoris Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.7. Thailand
      • 7.4.7.1. Thailand Angina Pectoris Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5. Latin America
    • 7.5.1. Latin America Angina Pectoris Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.2. Brazil
      • 7.5.2.1. Brazil Angina Pectoris Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.3. Argentina
      • 7.5.3.1. Argentina Angina Pectoris Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6. Middle East and Africa
    • 7.6.1. Middle East and Africa Angina Pectoris Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.2. South Africa
      • 7.6.2.1. South Africa Angina Pectoris Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.3. Saudi Arabia
      • 7.6.3.1. Saudi Arabia Angina Pectoris Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.4. UAE
      • 7.6.4.1. UAE Angina Pectoris Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.5. Kuwait
      • 7.6.5.1. Kuwait Angina Pectoris Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis by Key Market Participants
  • 8.2. Company Categorization
  • 8.3. Company Heat Map Analysis
  • 8.4. Company Profiles
    • 8.4.1. Pfizer Inc.
      • 8.4.1.1. Participant's Overview
      • 8.4.1.2. Financial Performance
      • 8.4.1.3. Product Benchmarking
      • 8.4.1.4. Recent Developments/Strategic Initiatives
    • 8.4.2. Bayer AG
      • 8.4.2.1. Participant's Overview
      • 8.4.2.2. Financial Performance
      • 8.4.2.3. Product Benchmarking
      • 8.4.2.4. Recent Developments/Strategic Initiatives
    • 8.4.3. AstraZeneca
      • 8.4.3.1. Participant's Overview
      • 8.4.3.2. Financial Performance
      • 8.4.3.3. Product Benchmarking
      • 8.4.3.4. Recent Developments/Strategic Initiatives
    • 8.4.4. Gilead Sciences
      • 8.4.4.1. Participant's Overview
      • 8.4.4.2. Financial Performance
      • 8.4.4.3. Product Benchmarking
      • 8.4.4.4. Recent Developments/Strategic Initiatives
    • 8.4.5. Novartis AG
      • 8.4.5.1. Participant's Overview
      • 8.4.5.2. Financial Performance
      • 8.4.5.3. Product Benchmarking
      • 8.4.5.4. Recent Developments/Strategic Initiatives
    • 8.4.6. GlaxoSmithKline Plc.
      • 8.4.6.1. Participant's Overview
      • 8.4.6.2. Financial Performance
      • 8.4.6.3. Product Benchmarking
      • 8.4.6.4. Recent Developments/Strategic Initiatives
    • 8.4.7. Merck & Co., Inc.
      • 8.4.7.1. Participant's Overview
      • 8.4.7.2. Financial Performance
      • 8.4.7.3. Product Benchmarking
      • 8.4.7.4. Recent Developments/Strategic Initiatives
    • 8.4.8. Amgen Inc.
      • 8.4.8.1. Participant's Overview
      • 8.4.8.2. Financial Performance
      • 8.4.8.3. Product Benchmarking
      • 8.4.8.4. Recent Developments/Strategic Initiatives
    • 8.4.9. Eli Lilly and Company
      • 8.4.9.1. Participant's Overview
      • 8.4.9.2. Financial Performance
      • 8.4.9.3. Product Benchmarking
      • 8.4.9.4. Recent Developments/Strategic Initiatives
    • 8.4.10. Otsuka Pharmaceutical Co., Ltd.
      • 8.4.10.1. Participant's Overview
      • 8.4.10.2. Financial Performance
      • 8.4.10.3. Product Benchmarking
      • 8.4.10.4. Recent Developments/Strategic Initiatives
    • 8.4.11. Sanofi S.A.
      • 8.4.11.1. Participant's Overview
      • 8.4.11.2. Financial Performance
      • 8.4.11.3. Product Benchmarking
      • 8.4.11.4. Recent Developments/Strategic Initiatives
    • 8.4.12. Boehringer Ingelheim International GmbH
      • 8.4.12.1. Participant's Overview
      • 8.4.12.2. Financial Performance
      • 8.4.12.3. Product Benchmarking
      • 8.4.12.4. Recent Developments/Strategic Initiatives